Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:45 ET | 4602 | 0.82 |
09:48 ET | 250 | 0.8151 |
09:50 ET | 100 | 0.8102 |
09:57 ET | 100 | 0.8102 |
10:01 ET | 2500 | 0.819999 |
10:10 ET | 100 | 0.8103 |
10:12 ET | 510 | 0.8199 |
10:15 ET | 762 | 0.8199 |
10:17 ET | 781 | 0.82 |
10:24 ET | 100 | 0.795 |
10:26 ET | 4000 | 0.795001 |
10:37 ET | 100 | 0.8 |
10:42 ET | 100 | 0.8 |
10:51 ET | 100 | 0.795 |
10:57 ET | 200 | 0.8 |
11:08 ET | 430 | 0.8015 |
11:11 ET | 200 | 0.8022 |
11:13 ET | 500 | 0.8 |
11:24 ET | 100 | 0.795 |
11:40 ET | 650 | 0.795 |
11:49 ET | 2900 | 0.790101 |
11:51 ET | 100 | 0.7901 |
11:54 ET | 4700 | 0.8139 |
11:58 ET | 701 | 0.81 |
12:09 ET | 200 | 0.81 |
12:12 ET | 424 | 0.8 |
12:20 ET | 100 | 0.814 |
12:34 ET | 100 | 0.8001 |
12:56 ET | 100 | 0.8001 |
01:14 ET | 851 | 0.8145 |
01:19 ET | 101 | 0.8201 |
01:21 ET | 6000 | 0.819 |
02:08 ET | 220 | 0.823 |
02:13 ET | 100 | 0.82 |
02:15 ET | 600 | 0.8319 |
02:20 ET | 601 | 0.8213 |
02:33 ET | 100 | 0.8001 |
02:51 ET | 100 | 0.8001 |
03:07 ET | 100 | 0.8001 |
03:23 ET | 100 | 0.8001 |
03:36 ET | 100 | 0.8001 |
03:43 ET | 700 | 0.8237 |
03:45 ET | 2334 | 0.83 |
03:48 ET | 700 | 0.83225 |
03:59 ET | 578 | 0.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 30.8M | -3.4x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 7.2M | -0.2x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 7.1M | 0.4x | +78.05% |
Qilian International Holding Group Ltd | 46.8M | -7.0x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.8M |
---|---|
Revenue (TTM) | $42.6M |
Shares Outstanding | 35.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-0.24 |
Book Value | $0.64 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -22.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.